Concord Biotech Limited is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022 (Source: F&S Report), supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan.

The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider.

Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.

For year/ period ended ( in Cr.)

• Established presence across the complex fermentation value chain;
• Global leadership in immunosuppressant APIs along with a wide spectrum of complex fermentation-based APIs across multiple therapeutic areas;
• Scaled manufacturing facilities with a consistent regulatory compliance track record and supported by strong R&D capabilities;
• Diversified global customer base with long-standing relationships with key customers;
• Experienced Promoters, management team supported by marquee investors;
• Financial track record of rapid growth and consistent profitability with healthy cash flows and strong shareholder returns

1. Achieve the benefits of listing the Equity Shares on the Stock Exchanges and
2. Carry out the Offer for Sale of up to 20,925,652 Equity Shares by the Selling Shareholder.

The company is an Indian biopharma company with many niche products. This entire issue is by way of OFS and no fund is going to the company. Well-informed investors may park funds for the medium to long-term rewards.